MPS收購引發光大證券人事震盪:光大資本原總裁代衛國被查 光大新鴻基原總裁被黨內警告
格隆匯12月9日丨據一財,從權威人士處瞭解到,MPS項目主要操刀人、原光大資本總裁代衛國被有關部門調查,事涉暴風集團與光大資本共同成立基金收購境外體育傳媒公司MPS事件。
據瞭解,代衛國系與薛峯同一時間被有關部門帶走調查,時間約爲今年7月中旬。另據瞭解,可能參與了MPS併購案的一位子公司老總李炳濤,因違反中央八項規定,近日被光大證券內部給予黨內嚴重警告處分。李炳濤亦系2015年光大證券收購香港新鴻基金融集團的主要操刀人,並出任光大證券兩家重要香港公司的行政總裁和總經理。
這場收購因估值過高被市場人士不少詬病,而此後被收購公司的不良業績表現,更是讓光大證券承受了數億元商譽減值損失。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.